Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicity in Melanoma: Current Evidence and Practical Clinical Management

Andrea Bottardi, Gabriele Busin, Lam Nguyen, Paolo Del Fiore, Giorgia Alberti, Andrea Danese, Michele Nori, Raimondo Pittorru, Fortunato Cassalia

Open source

DOI
10.3390/cancers18183041
Published
2026-09-19
Container
Cancers
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers18183041,
  title = {Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicity in Melanoma: Current Evidence and Practical Clinical Management},
  author = {Andrea Bottardi and Gabriele Busin and Lam Nguyen and Paolo Del Fiore and Giorgia Alberti and Andrea Danese and Michele Nori and Raimondo Pittorru and Fortunato Cassalia},
  year = {2026},
  journal = {Cancers},
  doi = {10.3390/cancers18183041},
  url = {https://doi.org/10.3390/cancers18183041}
}

RIS

TY  - JOUR
TI  - Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicity in Melanoma: Current Evidence and Practical Clinical Management
AU  - Andrea Bottardi
AU  - Gabriele Busin
AU  - Lam Nguyen
AU  - Paolo Del Fiore
AU  - Giorgia Alberti
AU  - Andrea Danese
AU  - Michele Nori
AU  - Raimondo Pittorru
AU  - Fortunato Cassalia
PY  - 2026
JO  - Cancers
DO  - 10.3390/cancers18183041
UR  - https://doi.org/10.3390/cancers18183041
ER  - 

APA

Bottardi, A., Busin, G., Nguyen, L., Fiore, P. D., Alberti, G., Danese, A., Nori, M., Pittorru, R., & Cassalia, F. (2026). Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicity in Melanoma: Current Evidence and Practical Clinical Management. Cancers. https://doi.org/10.3390/cancers18183041

Source records